Ballan Rafael, Saad Susana Marta Isay
Department of Pharmaceutical and Biochemical Technology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, SP, Brazil.
Food Research Center, University of São Paulo, São Paulo 05508-080, SP, Brazil.
Foods. 2021 Oct 21;10(11):2528. doi: 10.3390/foods10112528.
The increasing prevalence of type 2 diabetes (T2DM) worldwide has become a burden to healthcare systems. In 2019, around 463 million adults were living with diabetes , and T2DM accounted for 90 to 95% of cases. The relationship between the gut microbiota and T2DM has been explored with the advent of metagenomic techniques. Genome-wide association studies evaluating the microbiota of these individuals have pointed to taxonomic, functional, and microbial metabolite imbalances and represent a potential intervention in T2DM management. Several microbial metabolites and components, such as imidazole propionate, trimethylamine, and lipopolysaccharides, appear to impair insulin signaling, while short-chain fatty acids, secondary bile acids, and tryptophan metabolites may improve it. In addition, the use of probiotics with the aim of transiently restoring the microbial balance or reducing the effects of microbial metabolites that impair insulin sensitivity has been explored. Herein, we critically review the available literature on the changes in the gut microbiota in T2DM together with potential adjuvant therapies that may improve the health status of this population.
全球2型糖尿病(T2DM)患病率的不断上升已成为医疗保健系统的负担。2019年,全球约有4.63亿成年人患有糖尿病,其中T2DM占病例的90%至95%。随着宏基因组技术的出现,肠道微生物群与T2DM之间的关系得到了探索。评估这些个体微生物群的全基因组关联研究指出了分类学、功能和微生物代谢物的失衡,并代表了T2DM管理中的一种潜在干预措施。几种微生物代谢物和成分,如咪唑丙酸、三甲胺和脂多糖,似乎会损害胰岛素信号传导,而短链脂肪酸、次级胆汁酸和色氨酸代谢物可能会改善胰岛素信号传导。此外,人们还探索了使用益生菌来暂时恢复微生物平衡或减少损害胰岛素敏感性的微生物代谢物的影响。在此,我们批判性地回顾了关于T2DM患者肠道微生物群变化的现有文献,以及可能改善该人群健康状况的潜在辅助治疗方法。